Global Precision Cardiology Industry 2021-2031: Focus on Offering, Sample, Technology, Application, End-user, and Region
28 févr. 2022 06h28 HE
|
Research and Markets
Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Precision Cardiology Market - A Global and Regional Analysis: Focus on Offering, Sample, Technology, Application, End User, and Region - Analysis and...
前沿生物与AFFiRiS宣布就靶向PCSK9的高胆固醇血症治疗药物AFFITOPE®AT04达成大中华区许可协议
22 déc. 2021 04h00 HE
|
AFFiRiS AG
前沿生物获得在大中华区开发与商业化AFFITOPE®AT04的独家权利合作旨在加快AFFITOPE®AT04主动免疫疗法作为同类首创新药的全球开发进程，推动其在大中华区的临床开发和生产落地 中国南京和奥地利维也纳, Dec. 22, 2021 (GLOBE NEWSWIRE) --...
AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
22 déc. 2021 04h00 HE
|
AFFiRiS AG
Frontier Biotechnologies obtains exclusive rights to develop and commercialize AFFITOPE® AT04 in Greater China Collaboration accelerates the global development of AFFiRiS potential first-in-class...
ESPERION Announces Plan for Transformative Long-Term Growth
18 oct. 2021 07h00 HE
|
Esperion Therapeutics, Inc.
–Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial– –Reduces overall workforce by 40...
AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases
27 juil. 2021 08h00 HE
|
AFFiRiS AG
AFFiRiS to receive AC Immune stock valued at USD 58.7 million in exchange for its portfolio of therapeutics targeting alpha-synuclein and USD 5 million in cashAFFiRiS to focus on partnering to further...
AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology
27 mai 2021 05h00 HE
|
AFFiRiS AG
Repeated immunization with AFFITOPE® peptide active immunotherapy candidates AT04A and AT06A is safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune responseAT04A treatment...
Global Dyslipidemia Disease Analysis 2020-2027 - Market is Poised to Resume Steady Growth Due to the Introduction of Novel Agents
23 mars 2021 08h03 HE
|
Research and Markets
Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Dyslipidemia" report has been added to ResearchAndMarkets.com's offering. The report estimates that in 2018, there were...
ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
23 févr. 2021 16h01 HE
|
Esperion Therapeutics, Inc.
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third QuarterOver 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic...
ESPERION Appoints Sheldon Koenig as Chief Operating Officer
15 déc. 2020 07h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating...
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
10 nov. 2020 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal...